Literature DB >> 26138824

Nasal Chondromesenchymal Hamartoma (NCMH): a systematic review of the literature with a new case report.

Katrina Anna Mason1, Annakan Navaratnam2, Evgenia Theodorakopoulou3, Perumal Gounder Chokkalingam4.   

Abstract

BACKGROUND: Nasal chondromesenchymal hamartoma (NCMH) is a very rare, benign tumour of the sinonasal tract usually presenting in infants. We present a systematic review of NCMH cases alongside a case report of an adult with asymptomatic NCMH.
METHODS: A systematic review was conducted in accordance with PRISMA guidelines. A PubMed, EMBASE and manual search through references of relevant publications was used to identify all published case-reports of NCMH. Data was collected from each case-report on: patient demographics, laterality, size and location of NCMH, presentation, co-morbidities, investigations, treatment and follow-up.
RESULTS: The systematic review identified 48 patients (including ours): 33 male, 15 female. Mean age was 9.6 years (range: 1 day-69 years) with the majority aged 1 year or younger at presentation (n = 18). Presentations included: nasal congestion (n = 17), nasal mass (n = 15) and eye signs (n = 12). NCMH also involved the paranasal sinuses (n = 26), orbit (n = 16) and skull-base (n = 14). All patients underwent operative resection of NCMH. A small 2014 case-series found DICER1 mutations in 6 NCMH patients, establishing a link to the DICER1 tumour spectrum.
CONCLUSIONS: NCMH is a rare cause of nasal masses in young children and adults. In light of the newly established link between NCMH and DICER1 mutations surgeons should be vigilant for associated DICER1 tumours, as NCMH may be the 'herald tumour' of this disease spectrum.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26138824      PMCID: PMC4495949          DOI: 10.1186/s40463-015-0077-3

Source DB:  PubMed          Journal:  J Otolaryngol Head Neck Surg        ISSN: 1916-0208


Background

Nasal chondromesenchymal hamartoma (NCMH) is a very rare, benign tumour of the sinonasal tract. Forty-seven cases have been reported in the English literature and the vast majority of these presentations are in infants and young children often below the age of one. NCMHs have a mixed morphological structure comprised of predominantly mesenchymal and cartilaginous components. NCMH patients present with symptoms that are dependent on the location of the tumour in the nasal cavity or paranasal sinuses and their compression of local structures. These symptoms range from nasal obstruction to visual impairment and facial and dental pain. To date there have only been 6 cases of adult presentation of NCMH. Here we present the first systematic review of NCMH cases published in the literature to assess the patient demographics, presentation, management and prognosis of NCMH alongside a new and unusual case in an adult.

Case report

A 49-year-old man was referred to our outpatient clinic presenting with a small mass in his right nasal cavity. The lump, which the patient first noticed 5 years ago, had been growing insidiously over time and by the time of presentation had become visible at the right anterior naris. The patient did not complain of any symptoms but sought consultation as his wife was concerned by the cosmetic appearance of the mass. Examination revealed a large firm mass arising from the right side of the anterior nasal septum with approximately 0.5 cm attachment to the anterior cartilage of the septum. The left and right nasal cavities were otherwise unremarkable. Clinically, the mass had the appearance of a papilloma confined to the nasal cavity with an attachment to the septum only and therefore further imaging was not undertaken. The differential diagnoses considered at the time of presentation were: nasal polyp, squamous papilloma or inverted papilloma. The patient subsequently underwent excisional biopsy of the right nostril mass under general anaesthetic using a circumferential subperichondrial incision with a small margin. Intraoperatively, the mass had the macroscopic appearance of a 0.5 cm × 2 cm × 2 cm calcified nodule. Due to a small 0.5 cm base, subsequent healing was achieved by secondary intention aided by the routine application of topical antibacterial cream. Histopathological analysis showed the nodule to contain cartilage and aneurysmal bone covered in stratified squamous epithelium with keratinisation (Figs. 1 and 2). Histopathological diagnosis was made using a haematoxylin & eosin stain. These findings were consistent with a diagnosis of a nasal chondromesenchymal hamartoma.
Fig. 1

Nodule containing cartilage and aneurysmal bone and covered by stratified squamous epithelium with keratinisation (magnification ×25, haematoxylin & eosin stain)

Fig. 2

Areas of osteoid formation (magnification ×200, haematoxylin & eosin stain)

Nodule containing cartilage and aneurysmal bone and covered by stratified squamous epithelium with keratinisation (magnification ×25, haematoxylin & eosin stain) Areas of osteoid formation (magnification ×200, haematoxylin & eosin stain) The patient was followed up in clinic and was discharged after 2 years having shown no signs of recurrence. Furthermore, a telephone interview was conducted 4 years post operation and the patient reported no recurrence of the nasal mass. He confirmed that he had no post-operative complications and was happy with the outcome of the operation.

Methods

A systematic review was undertaken in accordance with PRISMA guidelines [1]. No systematic review protocol was used, however our systematic review methodology is described below and a four-phase flow diagram is represented in Fig. 3. All published case-reports of NCMH were included in the review. A PubMed search (MEDLINE) (1975 to May Week 2, 2015) was carried out using the following terms [(chondromesenchymal hamartoma) AND (nasal OR sinus OR maxillary OR ethmoid OR sphenoid OR frontal OR orbit OR cranial)]. An EMBASE search (1975 to May Week 2, 2015) was carried out using a best sensitivity-combination strategy. The PubMed search resulted in 32 citations of which 24 were relevant, 6 were not NCMH case-reports, one was a Chinese language case-report, and one case was a duplicate case-report publication [2]. An EMBASE search and a manual search through references of relevant publications yielded 11 further relevant citations. Of these only 6 were included in the analysis; one case was found to have been a duplicate case report [3, 4] and four other possible cases of NCMH were found through publication citation search, but were labelled as “Mesenchymal chondrosarcoma” [5] “nasal hamartoma” [6], “nasopharyngeal hamartoma” [7], and “congenital mesenchymoma” [8], and were therefore not included. Thirty-one publications that report 47 cases of NCMH were included in this systematic review. Data was collected on patient demographics (age, gender), laterality, size and site of NCMH, presentation, co-morbidities, investigations, treatment and follow-up. These were also the principle summary measures. Two authors performed the database search, the manual search through references of relevant publications, and extracted the relevant data from the case-reports. Data was entered into an Excel 2013 Microsoft Office™ database which was used to carry out basic statistical analysis.
Fig. 3

Four-phase flow diagram of systematic review in accordance with PRISMA guidelines * Two individual publications of single case-reports were excluded from analysis as these had previously been published, Schultz et al. [2] and Kang et al. [3].** See Table 1

Four-phase flow diagram of systematic review in accordance with PRISMA guidelines * Two individual publications of single case-reports were excluded from analysis as these had previously been published, Schultz et al. [2] and Kang et al. [3].** See Table 1
Table 1

Summary table of systematic review of NCMH cases reported in the literature

Author, Publication dateCase NoAge D/M/YSexSide & SizeSiteSymptomsCo-morbidityInvestigationsTreatmentFollow Up/
(1) McDermot, 1998 [10] USA15 DMND1. Nasal cavity1. Nasal MassNDCTSurgical excisionNo recurrence at2 years
2. Respiratory Difficulties
23 MFND1. Nasal cavity1. Nasal MassNDMRISurgical excisionNo recurrence at 2 years
2. Ethmoid Sinus2. Otitis Media
3. Intracranial extension
33 MMND1. Nasal cavity1. Choanal MassNDNDBiopsy then surgical excision Subsequent chemotherapyNo recurrence at 4 years
2. Respiratory distress
42 MMND1. Nasal cavity1. Nasal MassNDNDSurgical excisionNo recurrence at 18 months
2. Intracranial extension
512 DFND1. Nasal cavity1. Nasal MassNDCTSurgical excision & further re-excision after 16 monthsUnchanged persistent tumour in superior nasal cavity at 12 months
2. Intracranial extension
614 DMND1. Nasal cavity1. Nasal MassNDCTSurgical excision VP shunt for hydrocephalusResidual tumour in anterior cranial fossa at 9 months
2. Ethmoid sinus2. Hydrocephalus & agenesis of corpus callosum
3. Intracranial extension
77 YMND1. Nasal cavity1. Nasal MassPPBNDSurgical excisionNo recurrence at 2 months NB later reported by Priest et al. 2010 [27]- showed with multiple recurrences in first 3 years
2. Sphenoid sinus2. Nasal Congestion
(2) Chae 1999 Korea [30] *abstract only, Korean paper83 MFRight Size: 3.5 × 7.5 × 2.5 cm1. Nasal cavity1. EpistaxisNDCTSurgical excisionND
2. Ethmoid sinus2. Obstruction
3. Cribriform plate
(3) Kim D 1999 [31] USA93 MFRight Size: ND1. Nasal cavity1. Nasal massNone statedCT MRISurgical excision with mid-facial de-gloving and bi-frontal craniotomyNo recurrence at 18 months
2. Intracranial extension2. Otitis media
3. Ethmoid sinus
(4) Kato, 1999 [17] Japan104 MMLeft Size: ND1. Nasal cavity1. Nasal MassNone statedCTTwo stage surgical excision 1st intracranial/sinus lesion, 2nd intranasal lesionNo recurrence at 13 years
2. Intracranial extension2. Respiratory distress with cyanosis when feeding
3. Extension to left orbit3. Opthalmoplegia left eyeRadiotherapy post op
(5) Hsueh 2001 [32] Taiwan (2 cases)110 DMLeft Size: ND1. Nasal cavity1. Left facial swellingNone statedCT MRIExcision biopsy then subsequent surgical excision with lateral rhinotomy and craniofacial approachRecurrence after excision biopsy No recurrence at 5 years after second surgery
1. Sphenoid sinus2. Left nasal mass
3. Ethmoid sinus3. Respiratory distress & cyanosis when feeding
4. Compression of left orbit
4. Proptosis on recurrence
129 MMRight ND1. Nasal cavity1. Asymmetric faceNone statedCT MRISurgical resectionNo recurrence at 9 months
2. Maxillary sinus2. Right opthalmoplegia, enopthalmos and hypotropia
(6) Alrawi 2003 [14] Ireland1316 YMLeft 1.5 × 1.5 cm1. Nasal cavity1. Nasal swellingNone statedCT MRISurgical resection with delayed reconstruction with forehead flapNo recurrence at 8 months
(7) Shet, 2004 [21] India141 YMLeft Size: ND1. Nasal cavity1. Proptosis of left eyeNon statedCTChemotherapy (VID) as biopsy suggested spindle cell sarcoma- 30 % reduction in tumour size Then Left maxillectomy and surgical excisionResidual tumour at 1.5 years near eye but no further re-growth & stable
2. Extension into left orbit2. Left facial swelling
3. Ethmoid sinus
4. Sphenoid sinus
(8) Kim B, 2004 [22] Korea155 MMLeft Size: ND1. Nasal cavity1. Left eye ptosisNone statedCTFrontal craniotomy & trans-nasal surgical resectionND
2. Compression of left orbit
3. Defect left ethmoidal bone
4. Defects anterior cranial fossa
(9) Norman, 2004 [15] USA1611 YMLeft Size: ND1. Nasal cavity1. Headaches left sidedNone statedCTEndoscopic biopsy and anterior craniofacial resectionND
2. Displacement left orbital wall
(10) Ozolek, 2005 [11] USA (4 cases)1711 YMLeft Size: ND1. Nasal cavity1. Nasal massNone statedNDSurgery and care undertaken in another hospitalND Surgery and care undertaken in another hospital
2. Ethmoid sinus
3. Extension into left orbit
1817 YFND Size: ND1. Nasal cavity1. Nasal obstructionNone statedNDSurgical excisionND
2. Facial pain
1925 YMBilateral 8 × 5 × 3.5 cm1. Nasal cavity1. Respiratory distress from obstructing oropharyngeal tumour requiring emergency tracheostomy1. Multiple Intracranial vascular aneurysms 2. Longstanding nasopharyngeal tumour- biopsy aged 13 ‘chronic inflamed polyp’CTMultiple surgical resections within one year including, tracheostomy and initial surgical resection, further surgical resection of bulbar mass and nasal tumour, then Le-Fort osteotomy and further surgical resectionND
2. Maxillary sinus
3. Nasopharynx
2. Oropharynx2. Chronic sinusitis
2069 YFRight Size: ND1. Nasal cavityNDNone statedNDSurgical excisionND
2. Ethmoid sinus
(11) Low 2006 [33] UK2111 YMRight Size: ND1. Nasal cavity1. Nasal ObstructionNone statedCTSurgical excisionNo recurrence at 2 months
2. Epistaxis
(12) Johnson, 2007 [29] USA2215 YFBilateral Size: ND1. Nasal cavity1. Nasal obstruction1. PPBCTEndoscopic surgical excisionNo recurrence at 6 months
2. Nasopharynx2. Chronic sinusitis2. Sertoli-Leydig cell Ovarian Tumour
3. Congenital phthisi bulbi
(13) Silkiss, 2007 [18] USA237 MMRight 3.2 × 1.4 cm1. Nasal cavity1. PtosisNone statedCT MRISurgical resection- right lateral rhinotomyNo recurrence at 18 months
2. Erosion of cribriform plate2. Extropia
3. Compression of right orbit3. Strabismus 4. Stertor
(14) Nakagawa 2008 [34] Japan2412 YMLeft 1.5 cm1. Nasal cavity1. Nasal obstructionNone statedCTEndoscopic surgical resection and further endoscopic surgical resection after recurrenceRecurrence at 2 months No recurrence at 5 months post second surgery
2. Sphenoid sinus
3. Ethmoid sinus
4. Maxillary sinus
(15) Finitsis, 2009 [35] Greece2512 MMLeft 4 cm × 4.2 cm1. Nasal cavity1. Respiratory distressNone statedCT MRIPre-operative embolization Then Surgical resection with midface de-glovingND
2. Compression of left orbit
3. Maxillary sinus compression
4. Nasopharynx
(16) Kim J, 2009 [23] Korea2619 MMLeft 2.7 × 3.5 cm1. Nasal cavity1. Watery rhinorrhoeaNone statedCT MRIEndoscopic surgical resection ×2Recurrence at one year; 2nd surgery. No recurrence 10 months after second surgery
2. Orbital extension2. Nasal Obstruction
3. Intracranial extension
(17) Priest, 2010 [27] USA *case previously reported by McDermot et al. 1998 **case previously reported by Johnson et al. 2007 (2 new cases)-7 Y *MInitially unilateral, then bilateral1. Sphenoid sinus1. Nasal Congestion1. PPB type II–IIIFour resections over 3 yearsFollowed up for 13 years with multiple recurrences in first 3 years
2. Left Nasal cavity2. Nasal mass2. Lung cysts
-15 Y **FBilateral1. Bilateral nasal cavities1. Chronic Sinusitis1. PPB Type IISurgical resectionNo recurrence at 51 months
2. Bony erosion of posterior septum2. Facial Pain2. Sertoli-Leydig Cell Ovarian Tumour
2. Extending into nasopharynx3. Nasal Congestion3. Congenital phthisi bulbi Stickler syndrome
4. Nasal obstruction
2710 YFBilateral Size: ND1. Bilateral nasal cavities1. Nasal obstruction1. PPB Type IIICTSurgical resectionNo recurrence at 21 months
2811 YMRight Size: ND1. Nasal cavity1. Nasal obstruction1. PPB Type IIINDSurgical resectionNo recurrence at 4 months
2. Extension to anterior skull base
(18) Sarin, 2010 [24] India292.5 YMRight Size: ND1. Nasal cavity1. Right eye oculomotor impairmentNDMRIBiopsy and then lateral rhinotomy for excisionND
2. Maxillary, ethmoid and sphenoid sinus
3. Erosion of middle wall of orbit
(19) Eloy 2011 [25] Belgium3018 M*MRight 0.5 × 0.4 cm1. Nasal cavity1. Nasal obstructionNone statedCT MRIEndoscopic surgical resectionND
2. Ethmoid sinus2. Nasal mass
3. Extension into right orbit3. Hypertelorism, proptosis, diplopia
4. Intracranial extension4. Nasal swelling *symptoms 1st noticed at 2 months- delayed referral from Algeria to Brussels
(20) Jeyakumar 2011 [26] USA317 DFRight Size: ND1. Nasal cavity1. Nasal MassNone statedCT MRIEndoscopic surgical excisionND
2. Stertor
3. Proptosis right eye
(21) Mattos 2011 [20] USA323 YMLeft Size : ND1. Nasal cavity1. Eye infectionsNone statedCT MRIEndoscopic excision the further surgical excisionRecurrence at 21 months required further resection
2. Ethmoid sinus2. Eye congestion
3. Extension into right orbit3. Nasal obstruction
4. Left maxilla4. Cheek fullness
5. Intermitted left eye/face pain
(22) Behery, 2012 [36] USA3311 YMNDNDNasal Obstruction1. PPBSurgical resectionND
(23) Uzomefuna, 2012 [37] Ireland348 YMND1. Sphenoid sinus1. Frontal HeadacheNDCT MRIEndoscopic surgical resectionNo recurrence at 6 months
2. Ethmoid sinus
(24) Cho, 2013 [4] Korea3514 YMLeft 5 cm × 5.3 cm × 4 cm1. Nasal cavity1. Swelling and pain to left faceNone statedCTSubtotal maxillectomy, removal or orbital floor, removal of medial nasal mucous membrane. Reconstruction with iliac crest bone blockNo recurrence at 4 years
2. Maxillary sinus2. Tooth mobility
3. Intraoral
4. Orbital floor destruction
(25) Li Y, 2013 [12] China3640 YFBilateral Size: ND1. Nasal Cavity1. Nasal ObstructionNone statedCT MRIComplete radical resectionRecurrence at 3 months *Malignant transformation seen on histology
2. Maxillary sinus2. Bloody rhinorrhoea
3. Ethmoid sinus
(26) Li GY 2013 [9] China3723 YMLeft 3.2 × 2.5 cm1. Naval cavity1. Left Lacrimal SacNone statedNDEndoscopic surgical excisionNo recurrence at 3 months follow up
2. Extension to lacrimal sac & left orbit2. Proptosis
3. Ethmoid sinus3. Lateral displacement of globe
(27) Moon, 2014 [19] Korea389 MFRight Size: ND1. Nasal cavity1. Incomitant esotropia of right eye (inability to abduct right eye) No nasal symptomsNone statedCT MRISurgery and care undertaken in another hospitalND Surgery and care undertaken in another hospital
2. Maxillary sinus
3. Erosion of orbital wall
4. Erosion of cribriform plate
(28) Wang T, 2014 [38] China (2 cases)395 YMRight 2.5 × 3.6 × 4.3 cm1. Nasal cavity1. Recurrent sinusitisNone statedCT MRISurgical resectionNo recurrence at 3 years
2. Ethmoid sinus2. Nasal Obstruction
3. Intracranial extension
406 WFLeft 2.6 × 3.4 × 3.9 cm1. Nasal cavity1. Nasal obstructionNone statedCT MRISurgical resectionNo recurrence at 10 months
2. Pressure remodelling of adjacent bones2. Watery rhinorrhoea
(29) Obidan, 2014 [39] Saudi Arabia4114 Y Size: NDMBilateral1. Bilateral nasal cavities1. Nasal Obstruction1. PPBCTSurgical endoscopic resectionND
2. Decreased sense of smell
(30) Stewart, 2014 [13] USA **4 patients previously reported by Priest et al. 2010 [27] (4 new cases)-7 Y**MInitially unilateral, then bilateralND1. Nasal Congestion1. PPBSurgical resectionMultiple recurrences
2. Lung cysts
-15 Y**FBilateralND1. Chronic Sinusitis1. PPBSurgical resectionNo recurrence
2. Facial Pain2. Sertoli-Leydig Cell Ovarian Tumour
3. Nasal Congestion
-10 Y**FBilateralND1. Nasal congestion1. PPBSurgical resectionNo recurrence
-11 Y**MRightND1. Nasal Congestion1. PPBSurgical resectionNo recurrence
428 YMND Size: NDND1. ND1. PPBNDSurgical resectionNo recurrence
2. Pulmonary cysts in utero
3. Jejunal Polyps
4313 YFBilateral Size: NDND1. ND1. PPBNDSurgical resectionNo recurrence
2. Thyroid Papillary carcinoma
3. Sertoli-Leydig tumour
448 YMBilateral Size: NDND1. Chronic Sinusitis1. PPBNDSurgical resectionNo recurrence
456 YFND Size: NDNDND1. PPBNDSurgical resectionNo recurrence
2. Left cystic nephroma
3. Small bowel loop
4621 YFRight Size: NDND1. Nasal Congestion1. PPBNDSurgical resectionRecurrence at 4 years
2. Septal deviation2. Sertoli-Leydig Tumour
3. Nasal Obstruction (at recurrence)3. Multi-nodular goitre
(31) Chandra 2014 [40] India4712 YMRight Size: ND1. Nasal cavity1. Nasal ObstructionNone statedCT MRISurgical excisionNo recurrence at 5 months
2. Ethmoid sinus2. Proptosis
3. Extension into right orbit3. Right facial pain
(32) Mason 2015 UK4849 YMRight 0.5 × 2 × 2 cm1. Nasal cavity1. Nasal massNone statedNoneSurgical excisionNo recurrence at 4 years

Y Years, M Months, D Days, M Male, F Female, ND not documented, PPB Pleuropulmonary blastoma, CT Computed Tomography, MRI Magnetic Resonance Imaging

Results of systematic review

Forty-Eight NCMH patients (including our case) have been reported in the English literature (Fig. 3). Most cases presented in males; 33 male and 15 female, with a male to female ratio of 2.2:1 ratio. The mean age was 9.6 years (range: 1 day–69 years). A large proportion of these patients were aged 1 year or younger at presentation (n = 18) and only 8 adult patients (including our case) have been described. Site of pathology was limited to the nasal cavity only in 10 patients, and involved the paranasal sinuses (maxillary, ethmoid, sphenoid) in 26 patients, the orbit in 16 patients, extending to the skull base in 14 patients, had intracranial extension in 8 cases, involved the nasopharynx in 3 patients and the oropharynx in 2 patients (see Table 1). Summary table of systematic review of NCMH cases reported in the literature Y Years, M Months, D Days, M Male, F Female, ND not documented, PPB Pleuropulmonary blastoma, CT Computed Tomography, MRI Magnetic Resonance Imaging Clinical presentations of NCMH patients included: nasal congestion or obstruction (n = 17), nasal mass (n = 15), eye signs (proptosis, hypotropia, enopthalmos, strabismus, exotropia etc.) (n = 12), facial swelling (n = 8), headaches or facial pain (n = 6), stertor or respiratory distress (n = 8), ophthalmoplegia (n = 4), recurrent sinusitis (n = 4), rhinorrhoea (n = 3), otitis media (n = 2), epistaxis (n = 2), toothache (n = 1), hyposmia (n = 1), hydrocephalus (n = 1) and 4 patients were asymptomatic or had no signs and symptoms documented (see Table 1). All patients underwent operative resection of NCMH and the surgical approach was dependent on disease location. One patient had pre-operative chemotherapy due to initial misdiagnosis on biopsy as spindle cell sarcoma. One patient had pre-operative embolization to reduce operative blood loss. Follow up times were included for 24 patients, mean time for follow-up was 24 months, (range 2–156 months). Eleven patients were found to have persistent disease or disease recurrence on follow up, seven required further surgery, three patients were described as stable, and no further information was given on the other patient. Li et al. described the first and only reported case of malignant transformation of NCMH [9]. Thirty-six patients had no documented past medical problems. One adult patient had a history of multiple vascular aneurysms. Eleven of the patients had been diagnosed with pleuropulmonary blastoma (PPB) prior to NCMH detection. Of these 11 patients, 5 had other co-morbidities including three with Sertoli-Lleydig cell ovarian tumours, two with pulmonary cysts, one jejunal polyps, one papillary thyroid carcinoma, one cystic nephroma and one multinodular goitre. A potential weakness of this systematic review is the possibility of reporting bias through publication bias both within individual case reports and across the review. This reporting bias is three-fold: firstly in the incomplete publication of all the clinical aspects of the case-reports by the original authors, for example not reporting follow-up times or co-morbidities etc. Secondly it is possible that there have been cases of NCMH that have not been reported in the literature and can therefore not be included in the systematic review. Thirdly the exclusion of case-reports of “Mesenchymal chondrosarcoma” [5] “nasal hamartoma” [6], “nasopharyngeal hamartoma” [7], and “congenital mesenchymoma” [8] alongside others, which are published prior to the first description of NCMH by McDermot et al. in 1998, may have resulted in an underreporting of true NCMH cases. However without being able to retrospectively assess and re-classify the histology of these cases we feel it is appropriate to have excluded them from our analysis and conclusions. These sources of reporting biases could potentially reduce the validity of conclusions drawn in terms of not fully representing or capturing all possible cases of NCMH.

Discussion

NCMHs are predominantly benign lesions that are locally destructive and because of their aggressive appearance can be mistaken for a malignant tumour. However NCMHs can be slow growing and therefore have a delayed presentation. Histopathologically these lesions are analogous to other mesenchymal hamartomas, and consist of islands of chondroid tissue such as hyaline cartilage, areas of calcification, and mesenchymal cellular elements such as spindle cells and myxoid stroma. McDermott et al. were the first to recognise NCMH as a distinct clinic-pathological entity in 1998 when they described a case series of seven patients with a tumefactive process of the nasal passages and contiguous paranasal sinuses with a detectable mass in the nose [10]. In this case series, six of the seven patients were infants under the age of 3 months. As our systematic review demonstrates NCMH predominantly presents in young children and infants under the age of one, but there have now been seven case reports, including ours, of adults with NCMH up to the age of 69 [9, 11–14]. In 2013 the first and only reported case of malignant transformation of an NCMH was described in the literature [9]. In our case, the NCMH was initially thought to be a papilloma confined to the nasal septal wall and therefore further imaging was not undertaken prior to resection. However pre-operative imaging of these lesions provides valuable information regarding involvement of adjacent structures such as the paranasal sinuses, orbit and intracranial cavity. On computed tomography (CT) imaging, NCMH are typically seen as non-encapsulated, poorly defined masses often with cystic components [15]. Magnetic resonance imaging (MRI) of NCMH demonstrates a heterogeneous mass on T1 weighted images and T2 weighted images show the presence of cystic components. MRI also has the advantage of superior tissue characterisation and delineation of invasion of adjacent structures in comparison to CT [16]. Due to rarity of NCMH, even after thorough clinical and radiographic examination NCMH can be misdiagnosed, and differential diagnoses include: inverted papilloma, aneurysmal bone cysts or ossifying fibromas, nasoethmoidal encephalocoele, chondrosarcoma, nasal lymphoma, nasal glioma and rhabdomyosarcoma. Histopathological analysis following surgical resection is therefore needed for accurate diagnosis. Patients with NCMH most commonly present with symptoms of nasal obstruction, nasal mass, or eye signs, which reflects the involvement of NCMH in the nasal passages and orbit. Ophthalmic signs include signs of globe displacement such as strabismus, extropia, hypertelorism, proptosis, enophthalmus and ophthlmoplegia, direct results of the intra-ocular extension of NCMH or ocular compression by NCMH [17-26]. There has also been a report of a patient presenting with intra-oral symptoms due to involvement of the oral cavity [4]. Patients can therefore present to otolaryngology, ophthalmology or maxillo-facial departments and doctors in these specialties should be aware of this rare pathology. In our case, the patient did not complain of any cranial, ophthalmic or nasal symptoms but was aware of a slowly enlarging nasal mass. This is most likely due to the relatively small size of the tumour at the anterior nasal septum which did not obstruct the nasal passage. The aetiology of NCMH is thought to be due to an underlying genetic predisposition therefore accounting for the early presentation in the majority of cases. Priest et al. and Stewart et al. investigated patients with both NCMH and the rare paediatric dysembryonic sarcoma of the lung and pleura: pleuropulmonary blastoma (PPB) [13, 27]. In patients with NCMH and PPB Stewart et al. found germline DICER1 mutations in 6 out of 8 evaluated patients, and somatic DICER1 mutations in 2 out of those 6 patients with germline mutations [13]. This recent finding has established genetic proof of NCMH tumour association with DICER1 mutations and Stewart et al. therefore feel that NCMH should be considered part of the DICER1 tumour spectrum. The DICER1 familial tumour susceptibility syndrome confers an increased risk most commonly for pleuropulmonary blastoma (PPB) but also ovarian sex cord-stromal tumours; Sertoli-Leydig cell tumor [SLCT], juvenile granulosa cell tumour [JGCT] and gynandroblastomas. Less commonly the DICER1 tumour spectrum includes: cystic nephroma (CN), and thyroid gland neoplasia, multinodular goitres [MNG], adenomas, or differentiated thyroid cancers. The rarest observed tumours in this spectrum, alongside NCMHs, are ciliary body medulloepithelioma (CBME), botryoid-type embryonal rhabdomyosarcoma (ERMS) of the cervix or other sites, renal sarcomas, pituitary blastomas, and pineoblastomas [28]. Eleven patients in our systematic review had previous PPB and five of these also had other DIECR1 tumours. Surgeons and physicians should therefore be aware of these disease associations and should be vigilant of a diagnosis of NCMH in patients presenting with sino-nasal or orbital symptoms who have a history of any of these tumours. Johnson et al. importantly also point out that due to its location, NCMH is more likely to present early in life than the other DICER1 tumours [29]. Surgeons and physicians should therefore either offer DICER1 mutation analysis if available, or ensure long-term follow up of these patients and be vigilant for associated tumours, as NCMH may be the ‘herald tumour’ of this disease spectrum. There are also cases in the literature of children, adolescents and adults with NCMH who have had an asymptomatic infancy [9, 11, 12, 14]. This may imply that there are non-genetic components to NCMH pathogenesis. Alternatively it may simply reflect the insidious growth of the tumour or that some NCMH patients may only exhibit the phenotype later in life. However as this is an extremely rare pathology with only very recent formal association with the DICER1 mutation, the majority of the 42 reported cases have not had formal DICER1 mutation analysis. Therefore an association or lack thereof in the non-tested cases cannot be inferred. Successful management of NCMH entails complete resection in order to prevent recurrence. A complete excision however is not always technically feasible, especially in cases of intracranial extension of NCMH. An incomplete resection poses the risk of recurrence as well as the possibility of continued tumour growth and progressive symptoms. Nine patients in this systematic review were found to have disease recurrence, most likely from incomplete surgical excision.

Conclusions

We present an unusual case of NCMH in an adult without nasal obstructive symptoms due to the anatomical location of the NCMH attached to the nasal septum. A systematic review of the literature has highlighted that presentation is mostly related to tumour location, with nasal mass, nasal obstruction and ophthalmic signs being the most common forms of presentation. The majority of patients presenting with NCMH are children and infants below the age of one, but there have now been a few adult cases of presentation. Surgical resection is the treatment of choice with low recurrence rates in the majority of cases. There has only been one reported case of malignant transformation and NCMH is still considered a benign tumour. NCMH’s association with the DIECR1 mutation has very recently been established and therefore in light of this any patient with a DICER1-related tumour spectrum and new nasal or orbital symptoms should raise the suspicion of NCMH. Furthermore surgeons should subsequently be vigilant for associated DICER1 related tumours, as due to their location NCMHs may be the ‘herald tumour’ for this disease spectrum. This case and systematic review highlights the fact that NCMH can mimic other benign and malignant lesions and that surgeons and physicians should be aware of rare pathologies accounting for nasal masses.

Consent

Written consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the editor-in-chief of this journal.
  32 in total

1.  Nasal chondromesenchymal hamartoma in an adolescent.

Authors:  S E Low; R K Sethi; E Davies; J S Stafford
Journal:  Histopathology       Date:  2006-09       Impact factor: 5.087

2.  Ophthalmologic presentation of nasal chondromesenchymal hamartoma in an infant.

Authors:  Rona Z Silkiss; Sachin S Mudvari; Debra Shetlar
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2007 May-Jun       Impact factor: 1.746

3.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  J Clin Epidemiol       Date:  2009-07-23       Impact factor: 6.437

4.  Nasal chondromesenchymal hamartoma: correlation of typical MR, CT and pathological findings.

Authors:  Alice Yao-Lee; Maura Ryan; Veena Rajaram
Journal:  Pediatr Radiol       Date:  2011-03-12

5.  Congenital mesenchymoma transgressing the cribriform plate.

Authors:  J P Ludemann; T L Tewfik; K Meagher-Villemure; C Bernard
Journal:  J Otolaryngol       Date:  1997-08

Review 6.  Nasal chondromesenchymal hamartoma of infancy: the first Japanese case report.

Authors:  K Kato; R Ijiri; Y Tanaka; M Hara; K Sekido
Journal:  Pathol Int       Date:  1999-08       Impact factor: 2.534

7.  Nasopharyngeal hamartoma: report of a case and review of the literature.

Authors:  R J Zarbo; K D McClatchey
Journal:  Laryngoscope       Date:  1983-04       Impact factor: 3.325

8.  DICER1-pleuropulmonary blastoma familial tumor predisposition syndrome: a unique constellation of neoplastic conditions.

Authors:  Kris Ann Schultz; Jiandong Yang; Leslie Doros; Gretchen M Williams; Anne Harris; Douglas R Stewart; Yoav Messinger; Amanda Field; Louis P Dehner; D Ashley Hill
Journal:  Pathol Case Rev       Date:  2014-03

9.  Nasal chondromesenchymal hamartoma in children with pleuropulmonary blastoma--A report from the International Pleuropulmonary Blastoma Registry registry.

Authors:  John R Priest; Gretchen M Williams; William A Mize; Louis P Dehner; Michael B McDermott
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2010-09-06       Impact factor: 1.675

Review 10.  Nasal hamartoma: case report and review of the literature.

Authors:  M H Terris; G F Billman; S M Pransky
Journal:  Int J Pediatr Otorhinolaryngol       Date:  1993-12       Impact factor: 1.675

View more
  20 in total

Review 1.  Imaging Review of New and Emerging Sinonasal Tumors and Tumor-Like Entities from the Fourth Edition of the World Health Organization Classification of Head and Neck Tumors.

Authors:  K E Dean; D Shatzkes; C D Phillips
Journal:  AJNR Am J Neuroradiol       Date:  2019-02-14       Impact factor: 3.825

2.  Cystic renal mass in an infant with significant family history: Answers.

Authors:  Elsa Wynd; Peter Borzi; John Burke
Journal:  Pediatr Nephrol       Date:  2017-10-18       Impact factor: 3.714

Review 3.  Hamartomas from head to toe: an imaging overview.

Authors:  Francisca Leiter Herrán; Carlos S Restrepo; Daniel I Alvarez Gómez; Thomas Suby-Long; Daniel Ocazionez; Daniel Vargas
Journal:  Br J Radiol       Date:  2016-12-12       Impact factor: 3.039

Review 4.  A Systematic Review of Nasal Chondromesenchymal Hamartoma (NCMH) with a New Case Report.

Authors:  Etrat Javadirad; Javad Azimivaghar; Saba Montazer; Soraya Sharafi
Journal:  Head Neck Pathol       Date:  2022-05-04

Review 5.  Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Nasal Cavity, Paranasal Sinuses and Skull Base.

Authors:  Lester D R Thompson; Justin A Bishop
Journal:  Head Neck Pathol       Date:  2022-03-21

6.  Nasal Chondromesenchymal Hamartoma.

Authors:  Balamurugan Thirunavukkarasu; Debajyoti Chatterjee; Satyawati Mohindra; Bishan Dass Radotra; Shiv Jee Prashant
Journal:  Head Neck Pathol       Date:  2020-05-27

Review 7.  Pediatric Nasal Chondromesenchymal Tumors: Case Report and Review of the Literature.

Authors:  Daniel Schaerer; Javan Nation; Robert C Rennert; Adam DeConde; Michael L Levy
Journal:  Pediatr Neurosurg       Date:  2021-02-11       Impact factor: 1.162

8.  Nasal chondromesenchymal hamartomas in a cohort with pathogenic germline variation in DICER1.

Authors:  Lauren M Vasta; Alison Nichols; Laura A Harney; Ana F Best; Ann G Carr; Anne K Harris; Markku Miettinen; Kris Ann P Schultz; Hung Jeffrey Kim; Douglas R Stewart
Journal:  Rhinol Online       Date:  2020-04-13

Review 9.  THE "-OMAS" and "-OPIAS":  Targeted and Philosophical Considerations Regarding Hamartomas, Choristomas, Teratomas, Ectopias, and Heterotopias in Pediatric Otorhinolaryngologic Pathology.

Authors:  John A Ozolek; Merva Soluk Tekkesin
Journal:  Head Neck Pathol       Date:  2021-03-15

10.  Not just another nasal polyp: Chondro-osseous respiratory epithelial adenomatoid hamartomas of the sinonasal tract.

Authors:  Yue Yu; Chien Sheng Tan; Leslie Timothy Koh
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.